CD55 is over-expressed in the tumour environment

British Journal of Cancer

Volumn 84, Issue 1, 2001, Pages 80-86

  Li, L ^a   Spendlove, I ^a   Morgan, J ^a   Durrant, L G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

CD55 (DAF); Endothelium; Stroma; Tumour expression; Vascular endothelial growth factor (VEGF)

Indexed keywords

DECAY ACCELERATING FACTOR;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; COLORECTAL TUMOR; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNOLOGY;

ANTIGENS, CD55; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOHISTOCHEMISTRY; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0035136109     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1570     Document Type: Article

References (29)

1. Localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumours
2. Imaging of primary and metastatic colorectal cancer using In-111-labelled anti-tumour monoclonal antibody 791T/36
3. Human monoclonal anti-idiotypic antibody to the tumour associated antibody 791T/36
4. Increased expression of 791t-gp72 predicts a poor-prognosis in colorectal-cancer
5. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway
6. Mapping of epitopes, glycosylation sites and complement regulatory protein domains in human decay accelerating factor
7. Clinical outcome of colorectal-cancer patients treated with human monoclonal antiidiotypic antibody
8. Enhanced cell mediated tumour killing in patients immunised with human monoclonal anti-idiotypic antibody 105AD7
9. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55
10. 105AD7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses
11. Anti-tumour reactions of monoclonal antibody against a human osteogenic sarcoma cell line
12. Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody
13. Localisation of human osteosarcomas by anti-tumour monoclonal antibody
14. The 7-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)
15. Mechanisms by which the surface expression of the glycosylphosphatidylinositol anchored complement regulatory proteins decay accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines
16. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C
17. Culture of human endothelial cell derived from umbilical veins: Identification by morphological and immunological criteria
18. From TCR engagement to T cell activation: A kinetic view of T cell behaviour
19. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotype monoclonal antibody 105AD7
20. Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells
21. Structure and function of decay-accelerating factor CD55
22. Human carcinomas variably express the complement inhibitory proteins CD46 (Membrane Cofactor Protein), CD55 (Decay-Accelerating Factor), and CD59 (Protectin)
23. HU-LY-M5 a unique antigen physically associated with HLA molecules
24. Decay accelerating factor (CD55): A target for cancer vaccines?
25. A human glycoprotein that carries Cromer related blood group antigens on erythrocytes and is also expressed on leukocytes and platelets
26. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the inab phenotype
27. Activation of T cells via CD55: Recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion
28. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
29. The telomerase catalytic subunit is a widely expressed tumour-associated antigen recognised by cytotoxic T lymphocytes